From Amgen, Inc., South San Francisco, California 94080 and.
Amgen, Inc., Thousand Oaks, California 91320.
J Biol Chem. 2014 Oct 31;289(44):30470-30480. doi: 10.1074/jbc.M114.592022. Epub 2014 Sep 9.
The role of fibroblast growth factor receptor 4 (FGFR4) in regulating bile acid synthesis has been well defined; however, its reported role on glucose and energy metabolism remains unresolved. Here, we show that FGFR4 deficiency in mice leads to improvement in glucose metabolism, insulin sensitivity, and reduction in body weight under high fat conditions. Mechanism of action studies in FGFR4-deficient mice suggest that the effects are mediated in part by increased plasma levels of adiponectin and the endocrine FGF factors FGF21 and FGF15, the latter of which increase in response to an elevated bile acid pool. Direct actions of increased bile acids on bile acid receptors, and other potential indirect mechanisms, may also contribute to the observed metabolic changes. The results described herein suggest that FGFR4 antagonists alone, or in combination with other agents, could serve as a novel treatment for diabetes.
成纤维细胞生长因子受体 4(FGFR4)在调节胆汁酸合成中的作用已得到充分证实;然而,其在葡萄糖和能量代谢中的作用仍未得到解决。在这里,我们表明,FGFR4 基因敲除小鼠在高脂肪条件下,葡萄糖代谢、胰岛素敏感性得到改善,体重减轻。在 FGFR4 基因敲除小鼠中的作用机制研究表明,这些作用部分是通过增加血浆脂联素水平以及内分泌 FGF 因子 FGF21 和 FGF15 来介导的,后两者是响应升高的胆汁酸池而增加的。增加的胆汁酸对胆汁酸受体的直接作用,以及其他潜在的间接机制,也可能导致观察到的代谢变化。本文所述的结果表明,FGFR4 拮抗剂单独或与其他药物联合使用,可能成为治疗糖尿病的一种新方法。